Secondary end points were consistently improved in the VR-CAP group , including the complete response rate ( @ % vs. @ % ) , the median duration of complete response ( @ months vs. @ months ) , the median treatment-free interval ( @ months vs. @ months ) , and the @-year overall survival rate ( @ % vs. @ % ) .